Coave Therapeutics closes Series B
Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.
Coave Therapeutics, a clinical stage biotechnology company, has closed its Series B funding round at $39 million.
Copyright PEI Media
Not for publication, email or dissemination